However, although no serious adverse effects were found in cancer patients treated with IL-18, the efficacy was still limited due to increased expression of its high-affinity antagonist IL-18-binding protein (IL-18BP) in several cancers (Fabbi, Carbotti & Ferrini, 2015; Nakamura et al., 2018). This evidence concerns the gene IL18 and cancer.